CN106176597A - 一种传明酸传递体的制备方法 - Google Patents
一种传明酸传递体的制备方法 Download PDFInfo
- Publication number
- CN106176597A CN106176597A CN201610699408.1A CN201610699408A CN106176597A CN 106176597 A CN106176597 A CN 106176597A CN 201610699408 A CN201610699408 A CN 201610699408A CN 106176597 A CN106176597 A CN 106176597A
- Authority
- CN
- China
- Prior art keywords
- parts
- tranexamic acid
- chloroform
- probe
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims abstract description 25
- 229960000401 tranexamic acid Drugs 0.000 claims abstract description 25
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000000243 solution Substances 0.000 claims abstract description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 8
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 4
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 4
- 229960003964 deoxycholic acid Drugs 0.000 claims abstract description 4
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims abstract description 4
- 239000000839 emulsion Substances 0.000 claims abstract description 4
- 239000005457 ice water Substances 0.000 claims abstract description 4
- 235000015110 jellies Nutrition 0.000 claims abstract description 4
- 239000008274 jelly Substances 0.000 claims abstract description 4
- 239000012982 microporous membrane Substances 0.000 claims abstract description 4
- 239000008363 phosphate buffer Substances 0.000 claims abstract description 4
- 238000002390 rotary evaporation Methods 0.000 claims abstract description 4
- 239000007787 solid Substances 0.000 claims abstract description 4
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 4
- 239000000725 suspension Substances 0.000 claims abstract description 4
- 238000009210 therapy by ultrasound Methods 0.000 claims abstract description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 3
- 239000002953 phosphate buffered saline Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 230000014759 maintenance of location Effects 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 230000006837 decompression Effects 0.000 abstract 1
- 239000008055 phosphate buffer solution Substances 0.000 abstract 1
- 238000005303 weighing Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000013271 transdermal drug delivery Methods 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/044—Suspensions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
Abstract
一种传明酸传递体的制备方法，称取大豆卵磷脂300份（质量份数，下同），胆固醇150份于圆底烧瓶中，加200mL氯仿溶解，另取脱氧胆酸钠30份，传明酸60份，溶解于磷酸盐缓冲液（pH 7.0）中，再与上述氯仿溶液混合，探头式超声处理20s使形成W/O型乳剂，40℃减压旋蒸除氯仿，得半固体胶状物，再以50mL磷酸盐缓冲液水合，于冰水浴中探头式超声20s，以0.22μm微孔滤膜滤过，即得传明酸传递体混悬液。本发明的有益效果是：合成工艺简单，反应条件温和，生产成本较低，可重复性好，所制备的传明酸传递体能显著提高传明酸的透皮给药效果，还增强了传明酸在皮肤中的滞留量。
Description
技术领域
本发明涉及化学物质制备方法，具体的是一种传明酸传递体的制备方法。
背景技术
皮肤色素沉着是皮肤科临床常见的症状之一，也往往是患者就诊的主要原因。尽管没有皮肤痛、痒等痛苦，但皮肤或黏膜的颜色异常却使大多数人心理负担重，急于就诊。传明酸（tranexamic acid， TA）又名氨甲环酸、止血环酸，原为抗纤溶止血药物，它是继曲酸等美白剂后的又一个美白剂。不仅对皮肤的雀斑、老人斑、黄褐斑有消褪作用，而且对皮肤的滋润、皮肤灼伤后的愈合和粉刺等也有疗效。在有疗效化妆品的制备上，传明酸经常是以口服或注射的形式给药，常引起胃肠道反应及月经量的减少等不良反应。在透皮制剂方面主要以霜剂的形式进行使用。传递体作为一种透皮效果优于脂质体的新型透皮给药载体而备受关注。但目前对其作为传递体制剂，传明酸的研究相应较少。近年来，将生物活性用脂质体进行包封能有效地提高活性物质的透皮性，这已在医药、化妆品等领域得到广泛的应用。因此，将 TA 以传递体为载体进行包裹，可以使药物集中于皮肤角质层，形成药物贮库，缓缓向炎症部位释药，从而可以达到提高其生物利用度的目的。
发明内容
本发明所要解决的技术问题在于提供一种传明酸传递体的制备方法，提供一种新的制备方法。
本发明采用的制备方法，包括如下步骤：
称取大豆卵磷脂300份（质量份数，下同），胆固醇150份于圆底烧瓶中，加200mL氯仿溶解，另取脱氧胆酸钠30份，传明酸60份，溶解于磷酸盐缓冲液（pH 7.0）中，再与上述氯仿溶液混合，探头式超声处理20s使形成W/O型乳剂，40℃减压旋蒸除氯仿，得半固体胶状物，再以50mL磷酸盐缓冲液水合，于冰水浴中探头式超声20s，以0.22μm微孔滤膜滤过，即得传明酸传递体混悬液。
本发明的有益效果是：合成工艺简单，反应条件温和，生产成本较低，可重复性好，所制备的传明酸传递体能显著提高传明酸的透皮给药效果，还增强了传 明酸在皮肤中的滞留量。
具体实施方式
以下结合实例进一步说明本发明的内容，由技术常识可知，本发明也可通过其它的不脱离本发明技术特征的方案来描述，因此所有在本发明范围内或等同本发明范围内的改变均被本发明包含。
实施例：
称取大豆卵磷脂300份（质量份数，下同），胆固醇150份于圆底烧瓶中，加200mL氯仿溶解，另取脱氧胆酸钠30份，传明酸60份，溶解于磷酸盐缓冲液（pH 7.0）中，再与上述氯仿溶液混合，探头式超声处理20s使形成W/O型乳剂，40℃减压旋蒸除氯仿，得半固体胶状物，再以50mL磷酸盐缓冲液水合，于冰水浴中探头式超声20s，以0.22μm微孔滤膜滤过，即得传明酸传递体混悬液。
通过重复性实验，取同一批次供试品6份，分别进样测定传明酸的量，其RSD 为1.58%，结果表明，本方法重复性良好。
稳定性试验，取同一质量浓度的供试品溶液，分别在0、2、4、6、8、12 h 进样测定，传明酸峰面积的RSD为1.56%，结果表明供试品溶液在12h内稳定性良好。
本发明所制备的传明酸传递体与水溶液相比，不仅显著提高传明酸的透皮给药效果，还增强了传明酸在皮肤中的滞留量。其促进药物透皮吸收的机制可能是该制剂扰乱了皮肤角质层的紧密排列，使角质层结构变得疏松、无序从而提高皮肤对药物的渗透。传递体是一种新型透皮给药载体，将传明酸制备成传递体透皮给药，能够克服口服制剂的不良反应。因此，传明酸传递体具有广阔的应用前景。
Claims (1)
1.一种传明酸传递体的制备方法，包括如下步骤：
称取大豆卵磷脂300份（质量份数，下同），胆固醇150份于圆底烧瓶中，加200mL氯仿溶解，另取脱氧胆酸钠30份，传明酸60份，溶解于磷酸盐缓冲液（pH 7.0）中，再与上述氯仿溶液混合，探头式超声处理20s使形成W/O型乳剂，40℃减压旋蒸除氯仿，得半固体胶状物，再以50mL磷酸盐缓冲液水合，于冰水浴中探头式超声20s，以0.22μm微孔滤膜滤过，即得传明酸传递体混悬液。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610699408.1A CN106176597A (zh) | 2016-08-22 | 2016-08-22 | 一种传明酸传递体的制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610699408.1A CN106176597A (zh) | 2016-08-22 | 2016-08-22 | 一种传明酸传递体的制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106176597A true CN106176597A (zh) | 2016-12-07 |
Family
ID=57523329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610699408.1A Pending CN106176597A (zh) | 2016-08-22 | 2016-08-22 | 一种传明酸传递体的制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106176597A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109481321A (zh) * | 2018-12-17 | 2019-03-19 | 广州市晨茜化工有限公司 | 一种美白祛斑的传明酸柔性脂质体及其制备方法和应用 |
| CN120392564A (zh) * | 2024-01-17 | 2025-08-01 | 王叔和生物医药(武汉)有限公司 | 一种传明酸脂质体及其制备方法及应用 |
-
2016
- 2016-08-22 CN CN201610699408.1A patent/CN106176597A/zh active Pending
Non-Patent Citations (2)
| Title |
|---|
| ROOPESH SACHAN等: "DRUG CARRIER TRANSFERSOMES: A NOVEL TOOL FOR TRANSDERMAL DRUG DELIVERY SYSTEM", 《INTERNATIONAL JOURNAL OF RESEARCH AND DEVELOPMENT IN PHARMACY AND LIFE SCIENCES》 * |
| 李莎莎等: "传明酸传递体的制备及其性质考察", 《中草药》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109481321A (zh) * | 2018-12-17 | 2019-03-19 | 广州市晨茜化工有限公司 | 一种美白祛斑的传明酸柔性脂质体及其制备方法和应用 |
| CN120392564A (zh) * | 2024-01-17 | 2025-08-01 | 王叔和生物医药(武汉)有限公司 | 一种传明酸脂质体及其制备方法及应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018347514B2 (en) | Methods and compositions for topical delivery | |
| US20190008795A1 (en) | Compositions for topical application of compounds | |
| CN113694175B (zh) | 苦参碱基离子液体芋螺毒素多肽溶液、制剂及其制备方法与应用 | |
| CN104474551B (zh) | 褪黑素磷脂复合物、其透皮给药制剂及其制备方法 | |
| CN101474144A (zh) | 盐酸丁卡因脂质体凝胶及其制备方法 | |
| CN106176597A (zh) | 一种传明酸传递体的制备方法 | |
| CN104117066A (zh) | 外敷用抗甲状腺软膏的制备方法 | |
| CN101596300A (zh) | 中药开窍醒脑微乳鼻腔喷雾剂及其制备方法 | |
| CN104224691A (zh) | 一种盐酸莫西沙星的外用制剂及其制备方法 | |
| RU2506944C1 (ru) | Способ повышения трансдермальной проницаемости лечебных или косметических препаратов для наружного применения, способ введения в кожу газообразного ксенона | |
| WO2005074892A1 (fr) | Creme contenant des liposomes d'interferon | |
| CN102526112B (zh) | 一种缓释型珍珠明目滴眼液及其制备方法 | |
| CN114886878B (zh) | 18β-甘草次酸脂质体及其制备方法和应用 | |
| JPH0473413B2 (zh) | ||
| WO2024239066A1 (en) | Pharmaceutical composition | |
| CN110559258A (zh) | 一种四氢小檗碱凝胶及其制备方法和透皮率检测方法 | |
| KR100466757B1 (ko) | 생체에 펩티드성 약물을 유입시키기 위한 국소 제제 | |
| CN104490856A (zh) | 一种复方氢醌脂质体及其制备方法 | |
| WO2014076642A1 (en) | Topical composition for the transepidermal or transdermal delivery of paracetamol | |
| JPH044300B2 (zh) | ||
| CN1312105A (zh) | 一种治疗螨虫感染性皮肤疾病的外用脂质体制剂 | |
| CN119326740A (zh) | 一种治疗生物节律失调的鼻脑递释制剂 | |
| CN102232920A (zh) | 灯盏花素醇质体凝胶制剂及其制备方法 | |
| CN108143711A (zh) | 一种含有卢立康唑的外用乳膏组合物 | |
| CN117414365A (zh) | 酮康唑在制备治疗退行性骨关节炎的药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161207 |
|
| WD01 | Invention patent application deemed withdrawn after publication |